(Q28609425)

3 February 2017

1 reference

Europe PubMed Central

title

Developing novel treatments for mood disorders: accelerating discovery (English)

1 reference

3 February 2017

1 reference

7

Raymond Dingledine

1 reference

3 February 2017

1

Carol A. Tamminga

1 reference

3 February 2017

21

Trisha Suppes

1 reference

3 February 2017

Charles B. Nemeroff

2

1 reference

3 February 2017

Randy D. Blakely

3

1 reference

3 February 2017

Linda Brady

4

1 reference

3 February 2017

Cameron S. Carter

5

1 reference

3 February 2017

Kenneth L. Davis

6

1 reference

3 February 2017

Jack M. Gorman

8

1 reference

3 February 2017

Dimitri E. Grigoriadis

9

1 reference

3 February 2017

David C. Henderson

10

1 reference

3 February 2017

Robert B. B Innis

11

1 reference

3 February 2017

John Killen

12

1 reference

3 February 2017

Thomas P. Laughren

13

1 reference

3 February 2017

William M. McDonald

14

1 reference

3 February 2017

Greer M. M Murphy

15

1 reference

3 February 2017

Steven M. Paul

16

1 reference

3 February 2017

Matthew V. Rudorfer

17

1 reference

3 February 2017

Edward Sausville

18

1 reference

3 February 2017

Alan F. Schatzberg

19

1 reference

3 February 2017

Edward M. Scolnick

20

1 reference

3 February 2017

language of work or name

English

0 references

publication date

15 September 2002

1 reference

3 February 2017

published in

Biological Psychiatry

1 reference

3 February 2017

volume

52

1 reference

3 February 2017

issue

6

1 reference

3 February 2017

page(s)

589–609

1 reference

Diencephalic stimulation and the effects of ECT in endogenous depression

3 February 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Antidepressant-induced mania and cycle acceleration: a controversy revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Venlafaxine: a novel antidepressant that has a dual mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Comparison of bifrontal and bitemporal ECT for major depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Transient Acute Depression Induced by High-Frequency Deep-Brain Stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Rapid reversal of psychotic depression using mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

The effect of somatic treatment and comorbidity on immediate outcome in manic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Neurochemical individuality: genetic diversity among human dopamine and serotonin receptors and transporters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Neuroimaging studies of mood disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

A molecular and cellular theory of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Complementary therapies for depression: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Definition and epidemiology of treatment-resistant depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

A theory of convulsive therapy in endogenous depression: Significance of hypothalamic functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Imaging serotonergic neurotransmission in depression: hippocampal pathophysiology may mirror global brain alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Mirtazapine substitution in SSRI-induced sexual dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

The corticosteroid receptor hypothesis of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Initiation and adaptation: a paradigm for understanding psychotropic drug action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Applications of biochip and microarray systems in pharmacogenomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

The predictive power of haplotypes in clinical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Reboxetine: the first selective noradrenaline re-uptake inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Serotonin transporter gene polymorphism and antidepressant response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Augmentation strategies in patients with refractory depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Regional cerebral blood flow in mood disorders, III. Treatment and clinical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Paroxetine binding to the rat norepinephrine transporter in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

A SNPshot: pharmacogenetics and the future of drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Resistance to antidepressant medications and short-term clinical response to ECT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Consent and privacy in pharmacogenetic testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Effects of SSRIs on sexual function: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Pharmacogenetics and the practice of medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Dosage, seizure threshold, and the antidepressant efficacy of electroconvulsive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

ECT, research, and professional ambivalence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

A corticosteroid/dopamine hypothesis for psychotic depression and related states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Effectiveness of St John's wort in major depression: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Neurokinin(1) receptor antagonists as potential antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Asymmetric bilateral right frontotemporal left frontal stimulus electrode placement for electroconvulsive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Endogenous anticonvulsant substance in rat cerebrospinal fluid after a generalized seizure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Antidepressants: past, present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Parkinson's disease, depression, and electrical stimulation of the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Electrode placement in ECT: cognitive effects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901470-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(02)01470-1

0 references

1 reference